Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.

CONCLUSIONS: The mutational processes underpinning ECs vary even among tumors of the same TCGA molecular subtype and in the progression from primary to metastatic ECs. Only a minority of copy-number high (serous-like) ECs display genomics features of HRD and would likely benefit from HRD-directed therapies. PMID: 30415991 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30415991?dopt=Abstract

Source: Gynecologic Oncology - November 8, 2018 Category: Cancer & Oncology Authors: Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, Reis-Filho JS, Weigelt B Tags: Gynecol Oncol Source Type: research